The latest price target for Peak Bio (OTCPK:PKBO) was reported by Ladenburg Thalmann on November 4, 2022. The analyst firm set a price target for $15.00 expecting PKBO to rise to within 12 months (a possible 21328.57% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Peak Bio (OTCPK:PKBO) was provided by Ladenburg Thalmann, and Peak Bio initiated their buy rating.

There is no last upgrade for Peak Bio

There is no last downgrade for Peak Bio.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Peak Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Peak Bio was filed on November 4, 2022 so you should expect the next rating to be made available sometime around November 4, 2023.

While ratings are subjective and will change, the latest Peak Bio (PKBO) rating was a initiated with a price target of $0.00 to $15.00. The current price Peak Bio (PKBO) is trading at is $0.07, which is within the analyst’s predicted range.